<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00178399</url>
  </required_header>
  <id_info>
    <org_study_id>URCC 9700</org_study_id>
    <nct_id>NCT00178399</nct_id>
  </id_info>
  <brief_title>A Study For Using Radiosurgery On Limited Metastases</brief_title>
  <official_title>A Pilot Study For Using Radiosurgery On Limited Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The standard therapy in cases such as yours is surgery, radiation therapy, chemotherapy or
      hormonal therapy alone or in combination. The main purpose of this study is to evaluate
      whether radiosurgery alone affects your quality and length of life. A second purpose of this
      study is to determine if the levels of special types of protein (called cytokines) found in
      the blood are related to your quality of life during your course of treatment and follow-up.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this research study high dose stereotactic body radiation therapy will be directed at the
      site of metastasis. This treatment will be given once a day, 5 times a week (Monday through
      Friday) for one to four weeks depending on the location and size of the disease to be
      treated. Blood for the cytokine tests will be drawn before your therapy starts, weekly during
      therapy and at the follow-up visits as stated in the next paragraphs. Two to four tablespoons
      of blood will be removed each time.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2001</start_date>
  <completion_date type="Actual">March 15, 2007</completion_date>
  <primary_completion_date type="Actual">March 15, 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Curatively Treated Patients With Progression-free Survival</measure>
    <time_frame>24 months</time_frame>
    <description>Curatively treated patients were those with metastatic disease confined to the thorax and or with total metastases limited to five total lesions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Palliatively Treated Patients With Progression-free Survival</measure>
    <time_frame>24 months</time_frame>
    <description>Palliatively treated patients were those with more extensive disease wherein lung metastasis were considered the most life limiting component of their disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life and Correlation With Pro-apoptotic, Inflammatory, and Anabolic Cytokine Profiles</measure>
    <time_frame>30 months from date of registration.</time_frame>
    <description>Correlation of data from QOL questionnaires and blood markers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analyze Impact of Disease Bulk and Number of Sites Involved.</measure>
    <time_frame>From the date of radiation therapy treatment to the date of first failure or last follow-up, assessed up to 10 years</time_frame>
    <description>Analysis or response and progression.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">128</enrollment>
  <condition>Neoplasms, Metastatic</condition>
  <arm_group>
    <arm_group_label>Stereotactic body radiation therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stereotactic Body Radiation Therapy</intervention_name>
    <arm_group_label>Stereotactic body radiation therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Age ≥ 18 years

        KPS ≥ 70

        Palliative: Disease most likely to be life limiting, is definable, and treatable to a
        sterilizing dose according to protocol criteria.

        The size of the lesion must be such that it can be safely treated to sterilizing radiation
        doses according to the rules in the protocol

        Previously treated lesions are not eligible unless the prescribed dose can be safely
        delivered. Previously enrolled patients can be retreated to new lesions if they still meet
        protocol requirements.

        Informed consent must be obtained.

        Pregnancy test must be negative for women of child bearing potential.

        Out of state patients are eligible, if communication with the referring physicians is
        expected to be adequate to address the primary aim. The secondary aim (blood cytokines) is
        optional for out-of-state patients.

        Exclusion Criteria:

        Technical inability to achieve required dose based on safe dose constraints required for
        radiosurgery

        Women who are pregnant or nursing..

        Failure to meet inclusion requirements

        Contraindications to radiation.

        Patient should not be eligible for primary disease specific radiosurgical protocols
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Milano, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Rochester Department of Radiation Oncology</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <results_first_submitted>January 6, 2018</results_first_submitted>
  <results_first_submitted_qc>October 9, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 11, 2018</results_first_posted>
  <last_update_submitted>October 9, 2018</last_update_submitted>
  <last_update_submitted_qc>October 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Michael Milano, MD,PhD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Stereotactic Body Radiation Therapy</title>
          <description>Stereotactic Body Radiation Therapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="128"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Stereotactic Body Radiation Therapy</title>
          <description>Stereotactic Body Radiation Therapy</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="128"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" lower_limit="40" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Curatively Treated Patients With Progression-free Survival</title>
        <description>Curatively treated patients were those with metastatic disease confined to the thorax and or with total metastases limited to five total lesions.</description>
        <time_frame>24 months</time_frame>
        <population>Only curative patients were included in this analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Stereotactic Body Radiation Therapy</title>
            <description>Subjects received Stereotactic Body Radiation Therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Curatively Treated Patients With Progression-free Survival</title>
          <description>Curatively treated patients were those with metastatic disease confined to the thorax and or with total metastases limited to five total lesions.</description>
          <population>Only curative patients were included in this analysis</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Palliatively Treated Patients With Progression-free Survival</title>
        <description>Palliatively treated patients were those with more extensive disease wherein lung metastasis were considered the most life limiting component of their disease.</description>
        <time_frame>24 months</time_frame>
        <population>Only palliative patients were included in this analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Stereotactic Body Radiation Therapy</title>
            <description>Stereotactic Body Radiation Therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Palliatively Treated Patients With Progression-free Survival</title>
          <description>Palliatively treated patients were those with more extensive disease wherein lung metastasis were considered the most life limiting component of their disease.</description>
          <population>Only palliative patients were included in this analysis</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life and Correlation With Pro-apoptotic, Inflammatory, and Anabolic Cytokine Profiles</title>
        <description>Correlation of data from QOL questionnaires and blood markers.</description>
        <time_frame>30 months from date of registration.</time_frame>
        <population>No data was collected for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Stereotactic Body Radiation Therapy</title>
            <description>Stereotactic Body Radiation Therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life and Correlation With Pro-apoptotic, Inflammatory, and Anabolic Cytokine Profiles</title>
          <description>Correlation of data from QOL questionnaires and blood markers.</description>
          <population>No data was collected for this outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Analyze Impact of Disease Bulk and Number of Sites Involved.</title>
        <description>Analysis or response and progression.</description>
        <time_frame>From the date of radiation therapy treatment to the date of first failure or last follow-up, assessed up to 10 years</time_frame>
        <population>No data was collected for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Stereotactic Body Radiation Therapy</title>
            <description>Stereotactic Body Radiation Therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Analyze Impact of Disease Bulk and Number of Sites Involved.</title>
          <description>Analysis or response and progression.</description>
          <population>No data was collected for this outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Stereotactic Body Radiation Therapy</title>
          <description>Stereotactic Body Radiation Therapy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="123" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonitis/Pulmonary Infiltrates</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael Milano</name_or_title>
      <organization>University of Rochester</organization>
      <phone>585-273-4096</phone>
      <email>michael_milano@urmc.rochester.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

